Undersized angioplasty and stenting of symptomatic XXXX with Enterprise: Evaluation of clinical and vascular outcome.

@entity1 @entity64 @entity932 @entity63 @entity7244 @entity256 @entity1031 @entity715 @entity385 @entity4522
BACKGROUND: Severe @entity7244 results in more than 10% incidence of @entity64 and transient @entity63 attack. Using undersized angioplasty with off-label closed-cell Enterprise stent may be a feasible alternative option for treating @entity1 with @entity4522 who fail dual-antiplatelet medical therapy. The results of the authors' study are presented in this paper. MATERIALS AND METHODS: Between January 2013 and July 2014, 24 symptomatic @entity1 with a total of 30 intracranial arterial stenotic lesions refractory to medical therapy, who underwent undersized angioplasty and Enterprise stenting, were retrospectively reviewed in the authors' institution. The results evaluated include technical success rate, clinical outcome measured as modified Rankin Scale at presentation and follow-up, peri-procedural morbidity within 30 days and 1 year, and follow-up vessel patency. RESULTS: Stent deployment was successfully achieved in all stenotic lesions (30/30). Mean pre-stent and post-stent diameter residual stenosis was 81% and 18%, respectively. The peri-procedural complication rate during 30 days after stenting was 10% per lesion (3/30), including @entity932 , in-stent @entity715 and @entity385 . No further @entity1031 event or complication occurred in any @entity1 more than 30 days after stenting. Modified Rankin scale    <=   2 was observed in 64% and 83% of @entity1 at initial presentation and follow-up (mean 15.8 months), respectively. Imaging follow-up was available in 17 of 24 @entity1 (70.8%) and 20 of 30 treated lesions (66.6%) with a mean follow-up period of 15.4 months. Only one asymptomatic in-stent @entity256 occurred in 20 available lesions (5.0%). CONCLUSION: This preliminary study suggests that using undersized angioplasty and Enterprise stenting may effectively treat high-degree symptomatic @entity7244 with favorable clinical and angiographic outcome.
